TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04456374

Intervention type: OTHER
Intervention: Performance testing
Description: Soccer-specific performance will be evaluated by measuring flexibility, jumping ability, maximum speed, repeated spring ability, agility and endurance.

Intervention type: OTHER
Intervention: Performance testing
Description: Soccer-specific performance will be evaluated by measuring flexibility, jumping ability, maximum speed, repeated spring ability, agility and endurance.
Study: NCT02665273

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Greater occipital nerve block
Description: Bilateral greater occipital nerve block
Study: NCT01383590

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cat-PAD
Description: Intradermal injection 1 x 4 administrations 4 weeks apart.
Study: NCT02892552

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Multiple Detector Computed Tomography (MDCT)
Description: Patients had a usual MDCT, before having an additional Cone Beam Computed Tomography
Study: NCT00693095

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV-ALT + CMV-DCs
Description: CMV-ALT (3 X 10e7) with CMV-DCs (2 X 10e7)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV-ALT + Saline
Description: CMV-ALT (3 X 10e7) with Saline
Study: NCT02905032

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Decision Aid
Description: Observation of clinical encounter using the electronic decision aid to facilitate treatment option conversation between clinician and patient.
Study: NCT04201197

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inje cocktail
Description: Acute drug exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inje cocktail
Description: Acute drug exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inje cocktail
Description: Acute drug exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC Cannabis extract
Description: Acute drug exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC/CBD Cannabis Extract
Description: Acute drug exposure
Study: NCT02829476

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Osteoblast sample
Description: culture osteoblasts obtained from vertebrae fragments from 30 patients with AIS and from 10 control patients with secondary scoliosis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Osteoblast sample
Description: culture osteoblasts obtained from vertebrae fragments from 30 patients with AIS and from 10 control patients with secondary scoliosis
Study: NCT02206360

Intervention type: PROCEDURE
Intervention: Endoscopic Ultrasound

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging (MRI)
Study: NCT02046603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 162 mg will be administered once a week by SC injection and as a single fixed dose, irrespective of body weight, for the treatment duration of 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 162 mg will be administered once a week by SC injection and as a single fixed dose, irrespective of body weight, for the treatment duration of 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMARDs
Description: Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study. The study protocol does not specify any particular therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Corticosteroids
Description: Stable oral corticosteroids doses (≤10 mg/day prednisone or equivalent) are allowed. The study protocol does not specify any additional detail on types of oral corticosteroids.
Study: NCT04251845

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: topical melatonin
Description: Topical melatonin at 3% concentration with dosage of 15 mg once daily will be applied on the lesion for 6 weeks followed by a follow up of 3 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Topical application of placebo once daily for 6 weeks with a follow up for 3 months
Study: NCT03191097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingavirin
Description: Ingavirin capsules 60 mg once daily, regardless of meal, for 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo, capsules daily for 5 days.
Study: NCT01453764

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Harvesting and Implantation of SVF
Description: The cell therapy in this study is composed of stem cells derived from a patient's own adipose tissue that are harvested by liposuction using tumescent technique and isolated in the laboratory. The Adipose SVF will be delivered via intravenous injection.
Study: NCT01174472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Transluminal Angioplasty (PTA)
Description: Angioplasty performed with the use of the novel paclitaxel eluting balloons

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty (PTA)
Description: Angioplasty performed with the use of conventional angioplasty balloons
Study: NCT02046603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate per investigator's discretion.
Study: NCT01843738

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Per standard of care
Study: NCT02665273

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Bupivacaine
Description: 0.5 cc of 0.5% bupivacaine injected intradermally
Study: NCT04627805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyPath tool
Description: MyPath is a reproductive decision support tool that utilizes a patient-centered approach to help women frame their reproductive decisions in the context of their goals, preferences, and health needs. This tool was developed by Dr. Lisa Callegari with funding from the Veterans Administration (VA) Health Services Research \& Development to be used in primary care settings with women veterans. It is conceptually grounded in Self-Determination Theory, which postulates that health care that meets patients' psychological needs in three key domains - autonomy, competence, and relatedness - will result in improved health behaviors and health outcomes. This is particularly relevant in reproductive health care, given the highly individualized and personal nature of these decisions, and the importance of centering a woman's aspirations and goals in her health care decision making.
Study: NCT01843738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: The starting dose of vemurafenib will be the patient's baseline tolerating dose, between 720 - and 960 mg PO bid.
Study: NCT02164305

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: No exercise training
Study: NCT01548131

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Psychoeducative group therapy
Description: 6 sessions during pregnancy and 1 after childbirth

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducative group therapy
Description: 6 sessions during pregnancy and 1 after childbirth
Study: NCT04482504

Intervention type: DIAGNOSTIC_TEST
Intervention: 3 tests: Posturography, Questionnaire, vitamin D
Description: Posturography platform Kistler 9281B Questionnaire focused on exercise activities and self-evaluation of postural stability The investigators also determine level of vitamin D in the blood.
Study: NCT03414216

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group 1 early offloading surgery
Description: As above.
Study: NCT03555227

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: USG PECS2 with Drug A (active)
Description: Ultrasound guided Pecs 2 blocks with 0.25% levobupivacaine
Study: NCT04020133

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: saphenous nerve block
Description: The skin is disinfected and the saphenous nerve is located via Ultrasound . the transducer is placed anteromedially, approximately at mid-thigh level a high-frequency linear probe 5Y12 MHz prepared in a sterile fashion (Phillips HD11) .~The block needle (Stimuplex; Braun Medical, Bethlehem, Pa), is inserted in plane in a lateral-to-medial orientation and advanced toward the femoral artery .Once the needle tip is visualized anterior to the artery and after careful aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection site . When injection of local anesthetic does not appear to result in its spread around the femoral artery, additional needle repositions and injections may be necessary.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: saphenous nerve block
Description: The skin is disinfected and the saphenous nerve is located via Ultrasound . the transducer is placed anteromedially, approximately at mid-thigh level a high-frequency linear probe 5Y12 MHz prepared in a sterile fashion (Phillips HD11) .~The block needle (Stimuplex; Braun Medical, Bethlehem, Pa), is inserted in plane in a lateral-to-medial orientation and advanced toward the femoral artery .Once the needle tip is visualized anterior to the artery and after careful aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection site . When injection of local anesthetic does not appear to result in its spread around the femoral artery, additional needle repositions and injections may be necessary.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: popliteal plexus block
Description: After doing saphenous nerve block , we will move distally with the artery in the adductor canal until it moves away from the sartorius muscle to enter adductor hiatus . here , we will inject L.A above artery and so , popliteal plexus block will be accomplished
Study: NCT03555227

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: USG PECS2 with Drug P (placebo)
Description: Ultrasound guided Pecs 2 blocks with placebo (0.9% saline)
Study: NCT04020133

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plain bupivacaine
Description: 15ml of plain bupivacaine 0.5% will be given in both blocks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plain bupivacaine
Description: 15ml of plain bupivacaine 0.5% will be given in both blocks
Study: NCT03555227

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration with Drug P (placebo)
Description: Wound infiltration at the end of surgery with Drug P (0.9% saline)
Study: NCT04020133

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.05 mg epinephrine
Description: 0.05 mg epinephrine will be added to bupivacaine in both blocks to prolong their duration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.05 mg epinephrine
Description: 0.05 mg epinephrine will be added to bupivacaine in both blocks to prolong their duration
Study: NCT03555227

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration with Drug A (active)
Description: Wound infiltration at the end of surgery with 0.25% levobupivacaine
Study: NCT03589794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AP10-602
Description: Glucopyranosyl Lipid A -liposome-Quillaja Saponaria 21 (GLA-LSQ).
Study: NCT04529200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrotherapy treatment
Description: physical therapy management like EMS IFT
Study: NCT04382131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NaCl Solution
Description: NaCl Solution prepared by participants at home using water and salt
Study: NCT01995084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]HX4
Description: 400 MBq \[F-18\]HX4, is administered in a single intravenous bolus injection, followed by a saline flush.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]HX4
Description: 400 MBq \[F-18\]HX4, is administered in a single intravenous bolus injection, followed by a saline flush.
Study: NCT03733288

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and training sessions
Description: Agents will be invited to attend sessions in intervention week 1, 3, 9, and month 6. Sessions will introduce (week 1) and reinforce (week 3, 9, month 6) the intervention aims, benefits of and ways to move more and sit less, with emphasis on active breaks. Feedback from baseline assessment will be provided and discussed in week 3 (health data) and 9 (activity data) and month 6 (health and activity data from the 12-week assessment). Each session will include discussion of daily standing/walking goals set by the research team, with timers and a goal log provided to participants in week 1 to enable self-monitoring. The Stand Up champions, and their role to encourage daily movement and sitting reduction through modelling and verbal support, will be communicated and reinforced in each session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and training sessions
Description: Agents will be invited to attend sessions in intervention week 1, 3, 9, and month 6. Sessions will introduce (week 1) and reinforce (week 3, 9, month 6) the intervention aims, benefits of and ways to move more and sit less, with emphasis on active breaks. Feedback from baseline assessment will be provided and discussed in week 3 (health data) and 9 (activity data) and month 6 (health and activity data from the 12-week assessment). Each session will include discussion of daily standing/walking goals set by the research team, with timers and a goal log provided to participants in week 1 to enable self-monitoring. The Stand Up champions, and their role to encourage daily movement and sitting reduction through modelling and verbal support, will be communicated and reinforced in each session.
Study: NCT03733288

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support emails
Description: Agents will receive support emails weekly (weeks 1-12) then monthly (months 4-9) across the intervention. Each email includes an infographic that encourages moving more and sitting less at work.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support emails
Description: Agents will receive support emails weekly (weeks 1-12) then monthly (months 4-9) across the intervention. Each email includes an infographic that encourages moving more and sitting less at work.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team leader training
Description: Team leaders in the participating organisation will be invited to attend a training session before the intervention starts. The training aims to enhance team leader's capabilities to demonstrate positive movement and sitting behaviours at work and promote call agents to sit less and move more at work. Team leaders will be asked to include the intervention as an agenda item in their weekly team meetings with their call agents and their 1:1 sessions with call agents. Team leaders will be encouraged to incorporate walking into their 1:1 meetings with call agents.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team leader training
Description: Team leaders in the participating organisation will be invited to attend a training session before the intervention starts. The training aims to enhance team leader's capabilities to demonstrate positive movement and sitting behaviours at work and promote call agents to sit less and move more at work. Team leaders will be asked to include the intervention as an agenda item in their weekly team meetings with their call agents and their 1:1 sessions with call agents. Team leaders will be encouraged to incorporate walking into their 1:1 meetings with call agents.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Height-adjustable workstation
Description: After baseline, agents in the SLAMM+ arm will have a height-adjustable workstation installed on their existing workplace desk. This will enable work in a seated or standing position, with flexibility to alternate between postures. Desk installation will occur with support from the onsite organisation health and safety team. The research team will brief participants on safe and effective workstation use. A laminated sheet will be fixed to each workstation to remind participants of safe and effective use.
Study: NCT01530295

Intervention type: DRUG
Group type: OTHER
Intervention: DOCETAXEL
Description: 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 3 times pre-op and 3 times after surgery

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: DOCETAXEL
Description: 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 3 times pre-op and 3 times after surgery
Study: NCT03409926

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acacia Gum
Description: dietary supplement will be added to the participant's usual diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acacia Gum
Description: dietary supplement will be added to the participant's usual diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Acacia Gum
Description: dietary supplement will be added to the participant's usual diet
Study: NCT02520011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvocidib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxantrone
Study: NCT04067128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coaching
Description: Brief telephonic intervention consisting of up to three phone calls
Study: NCT04254978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bomedemstat
Description: Oral administration
Study: NCT00644969

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Randomization 2:1 treatment to placebo
Study: NCT04529200

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electrotherapy treatment
Description: physical therapy management like EMS IFT
Study: NCT00644969

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline (CP-526,555)
Description: One week of titration up to 1mg bid and 11 weeks of dosing at 1mg bid
Study: NCT00099125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02430337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-Assisted SafeCare
Description: A technology-enhanced version of SafeCare

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SafeCare
Description: SafeCare, an evidence-based home visiting program
Study: NCT03946735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy as an Effective Treatment for Social Anxiety, Perfectionism, and Rumination
Description: Week one involved introducing CBT and assessing the negative effects of perfectionism, rumination, and social anxiety. Week two allowed participants to specify stressful social activities, stressful social situations, and enjoyable activities. Week three to week six allowed participants to identify automatic thoughts and thinking errors (for example, all or nothing thinking, self-criticism, dysfunctional schemas for self-evaluation, and unrealistic standards). Assignments were provided to participants with the content of exposure to anxiety evoking situations in the treatment sessions and at home. Achievable behavioural goals were set for participants in the treatment sessions and at home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy as an Effective Treatment for Social Anxiety, Perfectionism, and Rumination
Description: Week one involved introducing CBT and assessing the negative effects of perfectionism, rumination, and social anxiety. Week two allowed participants to specify stressful social activities, stressful social situations, and enjoyable activities. Week three to week six allowed participants to identify automatic thoughts and thinking errors (for example, all or nothing thinking, self-criticism, dysfunctional schemas for self-evaluation, and unrealistic standards). Assignments were provided to participants with the content of exposure to anxiety evoking situations in the treatment sessions and at home. Achievable behavioural goals were set for participants in the treatment sessions and at home.
Study: NCT01859494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NINJA 3 Investigational Blood Glucose Monitoring System
Description: Untrained subjects with diabetes self-tested capillary fingerstick and palm blood using the NINJA 3 Investigational Blood Glucose Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to reference method results obtained from subject capillary plasma.
Study: NCT00862186

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 'Fatigue Facts & Fixes'
Description: 'Fatigue Facts \& Fixes' is an evidence based educational resource for adolescents with cancer. It is a bright colored laminated 8.5x11 double sided page. One side features information on cancer-related fatigue: Why am I so tired? (description of cancer-related fatigue); What causes fatigue? (contributing factors - environmental, personal/behavioral, cultural/family/other, and treatment-related); and What can help me to not be so tired? (alleviating factors - environmental, personal/behavioral, cultural/family/other, and treatment-related). The other side is a 'Do Not Disturb' sign with a pillow graphic which adolescents can use in the hospital or at home when they need some quiet time and which may also serve to attract their interest to the resource.
Study: NCT00940212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2423
Description: oral, single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral administration and single dose
Study: NCT02995447

Intervention type: OTHER
Intervention: differences between surface and intracerebral EEG
Description: No intervention is performed. Im- and explantation of intracerebral electrodes is performed for clinical and not for study purposes. The only difference between study and non-study patients is that the surface as well as the intracerebral EEG is recorded and stored in the former, while it is discarded in the latter.
Study: NCT03430440

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apply CIPKA mode
Description: The newly developed computer-integrated patient-controlled analgesia (CIPCA) mode increases or decreases the basal infusion rate with the use of the patient's bolus button. Compared with the conventional mode in which only the basal infusion rate is set to be fixed, the CIPCA mode sets the basal infusion rate, the increase / decrease rate of basal rate, and the increment / decrement interval.